Back to Search Start Over

A human monoclonal anti-ANG2 antibody leads to broad antitumor activity in combination with VEGF inhibitors and chemotherapy agents in preclinical models.

Authors :
Brown JL
Cao ZA
Pinzon-Ortiz M
Kendrew J
Reimer C
Wen S
Zhou JQ
Tabrizi M
Emery S
McDermott B
Pablo L
McCoon P
Bedian V
Blakey DC
Source :
Molecular cancer therapeutics [Mol Cancer Ther] 2010 Jan; Vol. 9 (1), pp. 145-56. Date of Electronic Publication: 2010 Jan 06.
Publication Year :
2010

Abstract

Localized angiopoietin-2 (Ang2) expression has been shown to function as a key regulator of blood vessel remodeling and tumor angiogenesis, making it an attractive candidate for antiangiogenic therapy. A fully human monoclonal antibody (3.19.3) was developed, which may have significant pharmaceutical advantages over synthetic peptide-based approaches in terms of reduced immunogenicity and increased half-life to block Ang2 function. The 3.19.3 antibody potently binds Ang2 with an equilibrium dissociation constant of 86 pmol/L, leading to inhibition of Tie2 receptor phosphorylation in cell-based assays. In preclinical models, 3.19.3 treatment blocked blood vessel formation in Matrigel plug assays and in human tumor xenografts. In vivo studies with 3.19.3 consistently showed broad antitumor activity as a single agent across a panel of diverse subcutaneous and orthotopic xenograft models. Combination studies of 3.19.3 with cytotoxic drugs or anti-vascular endothelial growth factor agents showed significant improvements in antitumor activity over single-agent treatments alone with no apparent evidence of increased toxicity. Initial pharmacokinetic profiling studies in mice and nonhuman primates suggested that 3.19.3 has a predicted human half-life of 10 to 14 days. These studies provide preclinical data for 3.19.3 as a potential new antiangiogenic therapy as a single agent or in combination with chemotherapy or vascular endothelial growth factor inhibitors for the treatment of cancer.

Details

Language :
English
ISSN :
1538-8514
Volume :
9
Issue :
1
Database :
MEDLINE
Journal :
Molecular cancer therapeutics
Publication Type :
Academic Journal
Accession number :
20053776
Full Text :
https://doi.org/10.1158/1535-7163.MCT-09-0554